Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Change in Accured Expenses (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Change in Accured Expenses for 7 consecutive years, with -$295952.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 292.47% to -$295952.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 26.34% increase, with the full-year FY2025 number at $1.7 million, up 247.79% from a year prior.
  • Change in Accured Expenses was -$295952.0 for Q4 2025 at Outlook Therapeutics, down from $354702.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.2 million in Q2 2025 to a low of -$994707.0 in Q1 2025.